27 results
PRE 14A
krj099vdtci b0q32a
14 Apr 23
Preliminary proxy
5:00pm
8-K
EX-99.1
uhjjdc5
10 Nov 21
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
4:14pm
8-K
EX-99.1
qpgvehal
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
EX-99.1
3hop50ocp dlzqhae0x
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
t2i25mwsw0
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
EX-99.1
yu439aaipbgjs1 9q
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
DEF 14A
8mwo srmeqbrl3m1v8
22 Apr 21
Definitive proxy
12:35pm
8-K
EX-99.1
v7thwxs rlq2f6qiu6b
25 Mar 21
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
12:00am
10-K
gq5ni95owxu2outv6tsu
25 Mar 21
Annual report
12:00am
424B4
stqdxx1m gyg3
10 Jul 20
Prospectus supplement with pricing info
9:35pm